homeostasis, and DNA damage. Among the hits that passed this screening cascade, a 6-dialkylaminopyrimidine carboxamide series was prioritized for hit to lead optimization. Compounds from this series were active against clinical Mtb strains, while no cross-resistance to conventional antituberculosis drugs was observed. This suggested a novel mechanism of action, which was confirmed by chemoproteomic analysis
针对结核分枝杆菌(Mtb),筛选了约3.5万种化合物的BioFocus D
PI SoftFocus库,以鉴定具有抗结核活性的新型命中物。在
生物学分类试验中评估了这些命中物,以排除建议通过经常遇到的混杂作用机制起作用的化合物,包括抑制细胞色素bc 1的QcrB亚基。复杂,细胞壁稳态破坏和DNA损伤。在通过该筛选级联反应的命中方法中,优先选择6-二烷基
氨基嘧啶羧酰胺系列以进行命中优化。该系列化合物对临床Mtb菌株具有活性,而未观察到对常规抗结核药物的交叉耐药性。这表明了一种新的作用机理,通过
化学计量学分析得到了证实,从而将BCG_3193和BCG_3827鉴定为功能未知的系列的推定靶标。初步的结构活性关系研究得出了具有中等至有效抗结核活性并改善了理化性质的化合物。